-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Expands By 30.6%
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Expands By 30.6%
PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 4,700 shares, a growth of 30.6% from the July 31st total of 3,600 shares. Based on an average daily trading volume, of 4,100 shares, the days-to-cover ratio is currently 1.1 days.
Analyst Ratings Changes
PRTC has been the subject of several research reports. Piper Sandler raised their target price on PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a research note on Thursday, August 25th. SVB Leerink decreased their target price on PureTech Health from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, June 15th.
Get PureTech Health alerts:Institutional Investors Weigh In On PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. grew its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company's stock.
PureTech Health Trading Down 4.5 %
PRTC stock traded down $1.35 during trading hours on Tuesday, hitting $28.65. 200 shares of the stock traded hands, compared to its average volume of 5,304. PureTech Health has a one year low of $18.15 and a one year high of $54.39. The company has a current ratio of 2.54, a quick ratio of 2.22 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $25.13 and a 200 day simple moving average of $25.40.About PureTech Health
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Stories
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 4,700 shares, a growth of 30.6% from the July 31st total of 3,600 shares. Based on an average daily trading volume, of 4,100 shares, the days-to-cover ratio is currently 1.1 days.
纯易达健康公司(纳斯达克：PRTC-GET评级)是空头股数8月份大幅增长的目标。截至8月15日，空头股数共有4,700股，较7月31日的3,600股增长30.6%。以日均成交量4,100股计算，目前天数与回补比率为1.1天。
Analyst Ratings Changes
分析师评级发生变化
PRTC has been the subject of several research reports. Piper Sandler raised their target price on PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a research note on Thursday, August 25th. SVB Leerink decreased their target price on PureTech Health from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, June 15th.
PRTC一直是几份研究报告的主题。派珀·桑德勒在8月25日周四的一份研究报告中将其对PureTech Health的目标价从37.00美元上调至44.00美元，并给予该公司“增持”评级。SVB Leerink在6月15日(周三)的一份研究报告中将PureTech Health的目标价从70.00美元下调至66.00美元，并为该公司设定了“跑赢大盘”的评级。
Institutional Investors Weigh In On PureTech Health
机构投资者看好PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. grew its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company's stock.
一家对冲基金最近增持了PureTech Health股票。根据AWM投资公司在提交给美国证券交易委员会的最新Form 13F文件中的数据，第二季度该公司在PureTech Health Plc(纳斯达克代码：PRTC-GET评级)的股票增加了2,100.0%。该基金持有66万股该公司股票，在此期间又购买了63万股。截至最近提交的美国证券交易委员会申请文件，AWM Investment Company Inc.持有PureTech Health约2.32%的股份，价值2,513,000美元。机构投资者和对冲基金持有该公司2.32%的股票。
PureTech Health Trading Down 4.5 %
PureTech Health交易下跌4.5%
About PureTech Health
关于PureTech Health
(Get Rating)
(获取评级)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家临床阶段的生物治疗公司，在美国发现、开发和销售治疗炎症、纤维化和免疫、顽固性癌症、淋巴和胃肠道、神经和神经心理以及其他疾病的药物。该公司提供靶向M胆碱乙酰胆碱受体的KarXT，用于治疗阿尔茨海默病的精神分裂症和精神病；用于治疗雄激素性脱发、上皮老化和其他疾病的再生生物学平台；用于治疗慢性和急性炎症性疾病的免疫调节平台；用于从人体微生物群中分离出基于特定细菌群的口服疗法；以及用于治疗与抑郁症、多发性硬化症、COVID后和ICU以及癌症相关疾病相关的认知功能障碍的疗法。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
- 免费获取StockNews.com关于PureTech Health(PRTC)的研究报告
- 减震器：颠簸时代的3只低波动率红利股票
- 零售业：第二季度收益的赢家和输家
- Targa能否继续反弹以实现其价格目标？
- 在拒绝了AppLovin的报价后，Unity Software准备好重整旗鼓了吗？
- MarketBeat播客：云股票的时代可能就是现在
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
获得PureTech HealthDaily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对PureTech Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧